Study Suggests COVID-19 Antiviral Nirmatrelvir Only Benefits Older Adults
Researchers identified a total of 109,254 eligible CHS members with COVID-19 who were 40 years of age and older and at high risk for progression to severe disease.
Researchers identified a total of 109,254 eligible CHS members with COVID-19 who were 40 years of age and older and at high risk for progression to severe disease.
The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.
The expanded approval was based on data from two phase 3 studies, miniSTONE-2 and BLOCKSTONE.
Under the EUA, Jynneos can be administered either intradermally for individuals aged ≥18 years or subcutaneously for individuals aged <18 years.
An individual is considered fully vaccinated about 2 weeks after the second dose of Jynneos and 4 weeks after receiving ACAM2000.
The Agency warned that use of an alternate sample type (eg, blood, saliva) may lead to false test results.
Paxlovid is authorized for the treatment of mild to moderate COVID-19 in certain patients who are at high risk for progression to severe disease.
In total, 1.6 million doses of the Jynneos vaccine will be available this year.
The trial evaluated booster doses of the Omicron-adapted vaccine candidates.
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine.